HTT

Global Huntington's Disease Treatment Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
torsdag, september 14, 2023
General Health, Science, Health, Research, HD, Huntington's disease, Drug development, Prevalence, Dysphagia, SRX246, HTT, Somnolence, Senior counsel, Disease, ZFP, Quality of life, Brain, Toxicity, II, Compound annual growth rate, Aggression, Investment, Patient, Palliative care, Growth, Irritation, Treatment, Symptomatic treatment, HRQOL, Pharmaceutical industry, Nursing, Vaccine

The "Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The anticipated growth of the global Huntington's disease treatment market is poised to make a significant impact, with projections indicating it will reach a substantial USD 1,871.2 million by 2030, as detailed in this comprehensive report.
  • Huntington's disease, a rare inherited neurodegenerative condition, exerts its impact across multiple generations, severely affecting individuals between the ages of 30 and 50.
  • The symptomatic treatment segment accounted for the largest revenue share in 2022 owing to the product availability and patent protection.

First Tunisian study examining age of onset for biallelic mutations in Huntington's disease

Retrieved on: 
söndag, augusti 27, 2023
HD, Huntington's disease, Zygosity, University, HTT, Disease, Allele, Huntingtin, Mutation, Doctor of Philosophy, CAG, Movement, Patient, University of Lisbon, Parkinson's disease, International Congress on Tuberculosis, Autosome, Pharmaceutical industry, Vaccine

This Tunisian cohort study reported that the age of disease onset for patients with a homozygous mutation in the Huntingtin gene (HTT) did not differ significantly from that of heterozygous patients.

Key Points: 
  • This Tunisian cohort study reported that the age of disease onset for patients with a homozygous mutation in the Huntingtin gene (HTT) did not differ significantly from that of heterozygous patients.
  • The age of disease onset between the homozygous and heterozygous patients did not differ significantly.
  • Patients with smaller all were associated with a later age of onset, 62 years for homozygous and 74 years for heterozygous.
  • The number of CAG repeats and age of disease onset was shown to be inversely correlated for homozygous patients.

Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results

Retrieved on: 
torsdag, augusti 3, 2023
GLP, HD, GBA1, Gene, Ataxia, HTT, Conference call, Disease, Telephone, Neurocrine Biosciences, Neurocrine, TRACER, G&A, Huntington's disease, Research, Brain, CNS, Small RNA, SOD1, Novartis, Prion, FXN, MSH3, Annual general meeting, Cell, Toxicology, Mouse, Sirna Therapeutics, Growth, FDA, Therapy, ALS, IND, Neurology, Conference, Society, Sangamo Therapeutics, VY, D, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Voyager

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported second quarter 2023 financial and operating results.

Key Points: 
  • ET today -
    CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported second quarter 2023 financial and operating results.
  • Collaboration Revenues: Voyager had collaboration revenue of $4.9 million for the second quarter of 2023, compared to $0.7 million for the same period in 2022.
  • The increase was primarily due to revenue recognized during the second quarter of 2023 on the 2023 and 2019 strategic collaborations with Neurocrine Biosciences.
  • ET to discuss the second quarter 2023 financial and operating results.

Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results

Retrieved on: 
tisdag, maj 9, 2023
GBA1, Telephone, Neurocrine Biosciences, Neurocrine, TRACER, G&A, Huntington's disease, Cell, Toxicology, ALS, Neurology, DSM-IV codes, Gene, HTT, Disease, Research, Brain, SOD1, FXN, Sirna Therapeutics, Growth, FDA, IND, Conference, VY, D, Exercise, GLP, Biotechnology, Conference call, Therapy, HD, Central nervous system, Capsid, Doctor of Philosophy, Ataxia, Traffic barrier, CNS, MSH3, Annual general meeting, Mouse, AD, Society, Pharmaceutical industry, Vaccine, Voyager, Novartis

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported first quarter 2023 financial and operating results.

Key Points: 
  • ET today -
    CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported first quarter 2023 financial and operating results.
  • In March 2023, Voyager presented new data at the AD/PD 2023 Conference highlighting the differentiating characteristics resulting in the selection of VY-TAU01.
  • Early data were presented at the 18th Annual Huntington's Disease Therapeutics Conference held in Zagreb, Croatia, April 24 – 27, 2023.
  • ET to discuss the first quarter 2023 financial and operating results.

Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
fredag, maj 5, 2023
Exercise, PROTAC, KRAS, Neuron, CHDI, AACR, Senior, LRRK2, HTT, Survival, Everolimus, Clinical trial, Annual Meetings of the International Monetary Fund and the World Bank Group, CTA, Molecule, Research, Part, EOP, Genentech, Equity method, CBR, Sale, ARVN, Development, Incidence, Neuroscience, State Administrative Expenses, American Association for Cancer Research, Ribociclib, Quantum Leap, RAS, Patient, Administration, Enzyme inhibitor, Annual general meeting, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, IND, AR, Conference, Food, Pfizer, Breast cancer, Pharmaceutical industry, Dietary supplement, Copper, Medical imaging, Medical device, Cryptocurrency, Bayer, Gaius Papirius Carbo Arvina

NEW HAVEN, Conn., May 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • “We made substantial progress throughout the first quarter across all areas of our early- and late-stage pipeline,” said John Houston, Ph.D., president and chief executive officer at Arvinas.
  • Data are expected to be presented at a medical conference in the second half of 2023.
  • Revenues: Revenues were $32.5 million for the quarter ended March 31, 2023, as compared with $26.5 million for the quarter ended March 31, 2022.
  • Net Loss: Net loss was $81.9 million for the quarter ended March 31, 2023, as compared with $63.4 million for the quarter ended March 31, 2022.

Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform

Retrieved on: 
tisdag, april 25, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, DNA, Therapy, PAM, HTT, Allele, Gene editing, Life, Mutation, Protospacer adjacent motif, Brain, Rgn, RNA, AAV, Huntingtin, CAG, Indel, Genome, Patient, Collection, SNP, Liver, Ecosystem, R, PAMS, Gene, Conference, Vaccine

Life Edit’s presentations underscore the ability of its gene editing platform to selectively target disease-associated genetic factors to treat life-threatening diseases.

Key Points: 
  • Life Edit’s presentations underscore the ability of its gene editing platform to selectively target disease-associated genetic factors to treat life-threatening diseases.
  • Wild-type HTT protein is purported to be physiologically critical, hence selective editing of the mutant HTT (mutHTT) protein is necessary for therapeutic benefit.
  • AAV5-delivered Life Edit gene editing systems enabling allele-specific targeting of mutant HTT demonstrated dose-response reductions in striatal mutHTT protein with clinically meaningful reductions of >50% observed.
  • Our recent technology advancements will help us to further power the Life Edit gene editing platform, support our partners, and selectively build out our pipeline of innovative therapeutic candidates."

Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington's Disease Therapeutics Conference

Retrieved on: 
tisdag, april 25, 2023
Translation, Huntington's disease, HD, Medicines Discovery Catapult, Innovate UK, Therapy, HTT, Disease, Neurodegenerative disease, Hope, Head, Max, Antibody, Molecular medicine, Data analysis, Innovation, Drug discovery, Microglia, Entrepreneurship, Conference, Pharmaceutical industry, Vaccine, Huntingtin

CAMBRIDGE, England, April 25, 2023 /PRNewswire/ -- Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington's Disease at the annual CHDI Huntington's Disease Therapeutics Conference in Dubrovnik, Croatia, 24-27 April 2023.

Key Points: 
  • CAMBRIDGE, England, April 25, 2023 /PRNewswire/ -- Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington's Disease at the annual CHDI Huntington's Disease Therapeutics Conference in Dubrovnik, Croatia, 24-27 April 2023.
  • The data to be presented builds on a successful collaboration with Medicines Discovery Catapult and has been, in part, funded by two Innovate UK grants.
  • Young Kwon, Chief Executive Officer of Alchemab, said: "Huntington's Disease is a devastating neurodegenerative disorder and has proven to be very difficult to treat.
  • Presenter: Donna Finch, Head of Translational and Clinical Science, Alchemab Therapeutics
    Date and Time: Wednesday, April 26, Session III: Novel mechanisms, modalities, and candidates for HD therapeutics, 9:00am-12:20pm CEST

Alchemab Therapeutics to present data profiling a novel antibody to Huntingtin Exon 1 at the CHDI Annual Huntington's Disease Therapeutics Conference

Retrieved on: 
tisdag, april 25, 2023
Translation, Huntington's disease, HD, Medicines Discovery Catapult, Innovate UK, Therapy, HTT, Disease, Neurodegenerative disease, Hope, Head, Max, Antibody, Molecular medicine, Data analysis, Innovation, Drug discovery, Microglia, Entrepreneurship, Conference, Pharmaceutical industry, Vaccine, Huntingtin

CAMBRIDGE, England, April 25, 2023 /PRNewswire/ -- Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington's Disease at the annual CHDI Huntington's Disease Therapeutics Conference in Dubrovnik, Croatia, 24-27 April 2023.

Key Points: 
  • CAMBRIDGE, England, April 25, 2023 /PRNewswire/ -- Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it will present data on a potential first-in-class disease modifying therapeutic for Huntington's Disease at the annual CHDI Huntington's Disease Therapeutics Conference in Dubrovnik, Croatia, 24-27 April 2023.
  • The data to be presented builds on a successful collaboration with Medicines Discovery Catapult and has been, in part, funded by two Innovate UK grants.
  • Young Kwon, Chief Executive Officer of Alchemab, said: "Huntington's Disease is a devastating neurodegenerative disorder and has proven to be very difficult to treat.
  • Presenter: Donna Finch, Head of Translational and Clinical Science, Alchemab Therapeutics
    Date and Time: Wednesday, April 26, Session III: Novel mechanisms, modalities, and candidates for HD therapeutics, 9:00am-12:20pm CEST

Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

Retrieved on: 
tisdag, mars 7, 2023
European Society for Primary Immunodeficiencies, Gene, Neuro, Therapy, Ataxia, IND Culver Line, FXN, TRACER, Pfizer, HTT, IND, AAV, ALS, Conference, Congress, G&A, Exercise, DSM-IV codes, Neurocrine, Conference call, Cell, Toxicology, Central nervous system, D, CNS, Capsid, Research, SOD1, GLP, Growth, Sirna Therapeutics, CDMO, Neurology, Telephone, GBA1, ESGCT, Doctor of Philosophy, Neurocrine Biosciences, MSH3, Family, Vaccine, Pharmaceutical industry, Video game, Cryptocurrency, Novartis, Voyager

ET today -

Key Points: 
  • ET today -
    CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported fourth quarter and full year 2022 financial and operating results.
  • “The past year has been transformational for Voyager,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager.
  • Collaboration Revenues: Voyager had collaboration revenue of $(1.6) million for the fourth quarter of 2022, compared to $28.1 million for the same period in 2021.
  • ET to discuss the fourth quarter 2022 financial and operating results.

Hyperloop Technology Global Market Report 2022: Growing Demand for Efficient and Emission Free Mass-Transit Drives Investment - ResearchAndMarkets.com

Retrieved on: 
torsdag, december 22, 2022
Rail, Transportation, Transport, Public Transport, Travel, Government, Congestion, Transport, COVID-19, Vacuum, Royal commission, Hyperloop Transportation Technologies, GDP, USD, Vehicle, Solar energy, Hyperloop, Safety, European Commission, United Kingdom, HTT, Carbon, Virgin Hyperloop, Renewable energy, Rail transport, Growth

The "Hyperloop Technology Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hyperloop Technology Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The hyperloop has the potential to provide a sustainable solution to the growing demand for high-speed travel and alleviate the rising challenges in transportation.
  • Hyperloop Transportation Technologies (HTT), a company that is currently developing hyperloop technology, has started building its first full-scale transportation system in Toulouse, France.
  • Hyperloop Technologies and Hyperloop Transportation Technologies say that the first hyperloop will be built outside the USA.